The Regulatory Mechanisms of Electroacupuncture Intervention on Immune Cells in Herpes Zoster

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Herpes Zoster (HZ), caused by the Varicella-Zoster Virus (VZV), is a common infection characterized by localized pain and blistering, with higher incidence in females. HZ affects patients' physical health, mental well-being, and quality of life. The immune system is critical in HZ pathogenesis. Studies show acupuncture relieves pain, modulates immunity, and may lower postherpetic neuralgia (PHN) risk. However, evidence is limited on whether electroacupuncture (EA) alleviates HZ by modulating immune cells. Using mass cytometry (CyTOF), this study will analyze peripheral immune cell changes pre- and post-EA to explore its regulatory effects on HZ immunity. This study will recruit HZ patients and healthy controls (HC), dividing patients into medication-only and medication+EA groups to assess EA's potential immunomodulatory effects in HZ treatment.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 50
Maximum Age: 70
Healthy Volunteers: t
View:

• Meets HZ diagnostic criteria;

• Female, aged between 50 and 70 years;

• Disease duration ≤7 days, with no prior antiviral, analgesic, or other treatments;

• Herpetic lesions limited to the trunk, within 1 to 3 dermatomes;

• Willing to participate in the trial and has signed the informed consent form.

• No history of HZ or major cardiovascular, respiratory, digestive, urinary, hematologic, endocrine, or neurological diseases;

• Age-matched female HC volunteers for the HZ group;

• Clear consciousness and ability to communicate normally;

• Fully understands the study protocol, demonstrates good compliance, and is willing to cooperate with the study;

• Has signed a written informed consent form.

Locations
Other Locations
China
The Affiliated Hangzhou First People's Hospital
RECRUITING
Hangzhou
Contact Information
Primary
Yan Shi
tumingqi1230@163.com
13867439433
Backup
Mingqi Tu
403712321@qq.com
15700067213
Time Frame
Start Date: 2024-11-11
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 8
Treatments
Active_comparator: Drug group
Control group
Experimental: Drugs combined with electroacupuncture group
Observation group
Related Therapeutic Areas
Sponsors
Leads: First People's Hospital of Hangzhou

This content was sourced from clinicaltrials.gov